Adjuvant bleomycin, vincristine and cisplatin (BOP) for high-risk stage I non-seminomatous germ cell tumours: a prospective trial (MRC TE17).
about
Surveillance vs. adjuvant therapy of clinical stage I testicular tumors - a review and the SWENOTECA experienceEfficacy and toxicity of external-beam radiation therapy for localised prostate cancer: a network meta-analysisCanadian consensus guidelines for the management of testicular germ cell cancer.Who benefits from hypofractionated radiation therapy for clinically localized prostate cancer: evidence from meta-analysis.The management of low-stage non-seminomatous germ cell tumorsRadiation therapy in the management of locally advanced prostate cancer.Current management of testicular cancerAdjuvant treatment in the management of testis-confined germ cell tumours after orchidectomy.Randomised pilot study of dose escalation using conformal radiotherapy in prostate cancer: long-term follow-upProspective study of factors predicting adherence to medical advice in men with testicular cancer.Reducing treatment toxicities in the management of good prognosis testicular germ cell tumors.Observational study of prevalence of long-term Raynaud-like phenomena and neurological side effects in testicular cancer survivors.Treatment strategies for high-risk locally advanced prostate cancer.kV cone-beam CT-based IGRT: a clinical review.Management of clinical stage I nonseminomatous germ cell tumors.Current Concepts in Management of Stage I NSGCT.A comparison of clinical outcomes between three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for prostate cancer.Ion therapy of prostate cancer: daily rectal dose reduction by application of spacer gel.Prostate alpha/beta revisited -- an analysis of clinical results from 14 168 patients.Pain in Platin-Induced Neuropathies: A Systematic Review and Meta-Analysis.Adjuvant Therapy for Stage IB Germ Cell Tumors: One versus Two Cycles of BEP.
P2860
Q26865862-B7193D2D-6D83-4CAB-A3AF-CCCD7F6D3507Q33613683-4D9FA8A0-168A-4255-A511-F82D5EE35B78Q33753786-2CEB3FF9-E44C-4392-A8A8-7F03B4BF15C3Q35201788-45398549-24E4-4FD9-A201-E05DD1955121Q35569345-09C86F0C-F30C-406C-98D5-A4688769ED4FQ36456157-D11BF56B-CC32-4D3E-9002-8A9897F18722Q36566495-74BF6416-83A2-44D3-B91A-9479F2AFF431Q36896016-54E24BE1-6D46-4FD6-9A23-B33118D6F615Q37081939-62E97AED-15F8-4221-BCDA-A39F142BBA6DQ37334807-1ED4DFB6-8178-4C9E-A26B-7D1347231DA7Q37385388-97012130-5D4F-4169-9265-C40B14325629Q37478015-674FCA65-95E7-481D-A82A-73EB037A8A36Q37671592-6706F07A-22DF-49F3-BF14-3CBB7141F2AFQ37870806-CD5AEDA9-B493-4194-9695-6A6D44355EF3Q38220484-B8DCCD32-8086-42AB-A2E8-EBC94502997CQ39105754-72613384-41EC-45AD-9D4D-60D296615EE8Q39252193-CB40A6E0-88C3-44FC-8C94-86DEC8F7DD00Q39701751-DCE468D1-2A2F-45F8-BD81-4F200C9084EAQ45182086-F213042D-144C-4743-8378-7CE80C744B52Q48192466-E30CB4B3-1BF7-4075-8417-950481A9B219Q55317807-72E839FD-D8D4-409D-8DB2-418C65C923C9
P2860
Adjuvant bleomycin, vincristine and cisplatin (BOP) for high-risk stage I non-seminomatous germ cell tumours: a prospective trial (MRC TE17).
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Adjuvant bleomycin, vincristin ...... prospective trial (MRC TE17).
@ast
Adjuvant bleomycin, vincristin ...... prospective trial (MRC TE17).
@en
type
label
Adjuvant bleomycin, vincristin ...... prospective trial (MRC TE17).
@ast
Adjuvant bleomycin, vincristin ...... prospective trial (MRC TE17).
@en
prefLabel
Adjuvant bleomycin, vincristin ...... prospective trial (MRC TE17).
@ast
Adjuvant bleomycin, vincristin ...... prospective trial (MRC TE17).
@en
P2093
P2860
P356
P1476
Adjuvant bleomycin, vincristin ...... prospective trial (MRC TE17).
@en
P2093
D P Dearnaley
J D Graham
J T Roberts
M H Cullen
M P J Sokal
M V Williams
MRC Testicular Tumour Working Party
P2860
P2888
P304
P356
10.1038/SJ.BJC.6602624
P407
P577
2005-06-01T00:00:00Z